🔎 Trials Near Me

Home › Leucemia linfatica cronica › Ohio

Studi clinici su Leucemia linfatica cronica nello stato di Ohio

43 studi su Leucemia linfatica cronica cercano partecipanti presso sedi nello stato di Ohio.

Città nello stato di Ohio

Testo ufficiale dello studio (inglese)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  • Cleveland Clinic Akron General, Akron
  • OhioHealth O'Bleness Hospital, Athens
  • Avon - Richard E Jacobs Health Center, Avon
  • e altri 16
In reclutamentoFase 3
Età 65 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Summa Health System - Akron Campus, Akron
  • Cleveland Clinic Akron General, Akron
  • Summa Health System - Barberton Campus, Barberton
  • e altri 44
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

  • Study Site 104, Columbus
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07582432

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
  • Cleveland Clinic Foundation, Cleveland
  • Ohio State University Comprehensive Cancer Center, Columbus
  • e altri 2
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT04269902

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  • GC2202 Study Site 105, Canton
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT05645107

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  • Oncology Hematology Care Clinical Trials, Llc, Cincinnati
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT06943872

Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 2
Età 75 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07685717

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  • University Hospitals, Cleveland
  • Dayton Physician Network, Dayton
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT06846671

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • Dayton Physician Network, Dayton
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT06973187

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Oncology Hematology Care Inc, Cincinnati
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07218341

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • University of Cincinnati Medical Center, Cincinnati
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • University of Cincinnati, Cincinnati
  • The Cleveland Clinic Foundation, Cleveland
  • The Ohio State University, Columbus
  • e altri 1
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07221500

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 set 2026 · NCT07061951

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

  • Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT07225439

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

  • Research Site, Columbus
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06564038

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

  • The James Cancer Hospital and Solove Research Institute, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT05091424

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 31 ago 2026 · NCT07734038

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  • University of Cincinnatti Medical Center, Cincinnatti
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT06528301

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  • OSU Comprehensive Cancer Center, Columbus
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT07342478

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • The Ohio State University Wexner Medical Center, Columbus
In reclutamentoFase 1/2
Età da 13 a 90 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT06533579

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

  • University of Cincinnati, Cincinnati
  • The Ohio State University, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 31 lug 2026 · NCT06708897

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • University of Cincinnati Medical Center, Cincinnati
  • Cleveland Clinic, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 lug 2026 · NCT05131022

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 giu 2026 · NCT07271667

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

  • Nationwide Children's Hospital, Columbus
  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 1
Età 2 e oltre · Tutti i sessi · Aggiornato il 29 mag 2026 · NCT05418088

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • University of Cincinnati, Cincinnati
  • The Ohio State University, Columbus
In reclutamentoFase 1
Età 13 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT04771572

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • Gabrail Cancer Center Research,, Canton
In reclutamentoFase 1/2
Età da 12 a 95 · Tutti i sessi · Aggiornato il 15 apr 2026 · NCT04329728

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  • Cleveland Clinic Main Campus /ID# 271292, Cleveland
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 apr 2026 · NCT06428019

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 mar 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 mar 2026 · NCT06876649

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 feb 2026 · NCT06466122

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 feb 2026 · NCT05336812

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Gabrail Cancer & Research Center, Canton
  • The Ohio State University - The James Cancer Hospital, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 feb 2026 · NCT05544019

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

  • The Ohio State University /ID# 230439, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 feb 2026 · NCT04895436

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 gen 2026 · NCT05417165

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

  • The Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 gen 2026 · NCT06043674

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

  • University of Cincinnati, Cincinnati
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 gen 2026 · NCT07108998

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

  • University of Cincinnati, Cincinnati
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 gen 2026 · NCT07014917

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 dic 2025 · NCT06757647

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • Taylor Cancer Research Center, Maumee
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 dic 2025 · NCT05602363

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • University Hospitals Cleveland Medical Center, Cleveland
  • The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2025 · NCT05780034

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.